SEARCH

SEARCH BY CITATION

References

  • 1
    McMorrow RC, Mythen MG. Pulse oximetry. Curr Opin Crit Care 2006; 12: 269-271.
  • 2
    Wagner JL, Ruskin KJ. Pulse oximetry: basic principles and applications in aerospace medicine. Aviat Space Environ Med 2007; 78: 973-978.
  • 3
    Smith M. Shedding light on the adult brain: a review of the clinical applications of near-infrared spectroscopy. Philos Transact A Math Phys Eng Sci 2011; 369: 4452-4469.
  • 4
    Drayna PC, Abramo TJ, Estrada C. Near-infrared spectroscopy in the critical setting. Pediatr Emerg Care 2011; 27: 432-439; quiz 440-432.
  • 5
    Tromberg BJ, Cerussi A, Shah N, Compton M, Durkin A, Hsiang D, et al. Imaging in breast cancer: diffuse optics in breast cancer: detecting tumors in pre-menopausal women and monitoring neoadjuvant chemotherapy. Breast Cancer Res 2005; 7: 279-285.
  • 6
    Schaafsma BE, Mieog JS, Hutteman M, van der Vorst JR, Kuppen PJ, Lowik CW, et al. The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. J Surg Oncol 2011; 104: 323-332.
  • 7
    Liu Y, Bauer AQ, Akers WJ, Sudlow G, Liang K, Shen D, Berezin MY, et al. Hands-free, wireless goggles for near-infrared fluorescence and real-time image-guided surgery. Surgery 2011; 149: 689-698.
  • 8
    Tan X, Luo S, Wang D, Su Y, Cheng T, Shi C. A NIR heptamethine dye with intrinsic cancer targeting, imaging and photosensitizing properties. Biomaterials 2012; 33: 2230-2239.
  • 9
    Goldsmith SJ. Update on nuclear medicine imaging of neuroendocrine tumors. Future Oncol 2009; 5: 75-84.
  • 10
    Achilefu S, Dorshow RB, Bugaj JE, Rajagopalan R. Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging. Invest Radiol 2000; 35: 479-485.
  • 11
    van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med 2011; 17: 1315-1319.
  • 12
    Hsiung PL, Hardy J, Friedland S, Soetikno R, Du CB, Wu AP, Sahbaie P, et al. Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. Nat Med 2008; 14: 454-458.
  • 13
    Bremer C, Tung CH, Weissleder R. Molecular imaging of MMP expression and therapeutic MMP inhibition. Acad Radiol 2002;(9 suppl 2): S314-S315.
  • 14
    Lee H, Akers W, Bhushan K, Bloch S, Sudlow G, Tang R, et al. Near-infrared pH-activatable fluorescent probes for imaging primary and metastatic breast tumors. Bioconjug Chem 2011; 22: 777-784.
  • 15
    Urano Y, Asanuma D, Hama Y, Koyama Y, Barrett T, Kamiya M, et al. Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med 2009; 15: 104-109.
  • 16
    Urano Y, Sakabe M, Kosaka N, Ogawa M, Mitsunaga M, Asanuma D, et al. Rapid cancer detection by topically spraying a gamma-glutamyltranspeptidase-activated fluorescent probe. Sci Transl Med 2011; 3: 110ra119.
  • 17
    Caturelli E, Siena DA, Fusilli S, Villani MR, Schiavone G, Nardella M, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-long-term prospective study. Radiology 2000; 215: 123-128.
  • 18
    Velazquez RF, Rodriguez M, Navascues CA, Linares A, Perez R, Sotorrios NG, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. HEPATOLOGY 2003; 37: 520-527.
  • 19
    Kanematsu T, Furui J, Yanaga K, Okudaira S, Shimada M, Shirabe K. A 16-year experience in performing hepatic resection in 303 patients with hepatocellular carcinoma: 1985-2000. Surgery 2002; 131: S153-158.
  • 20
    Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988; 62: 479-483.